RxDoctor Payments Data

Angela Taylor

Family · Stonewall, LANPI 1942650429

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $130, 2.0 times the $63 reported in 2021. That places this record below the midpoint for family clinicians in LA, where the typical reported total is $521.

$410in general payments, 2019–2025

Across 19 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Revance Therapeutics, Inc.$72
  • Galderma Laboratories, L.p.$52
  • Dexcom, Inc.$50
  • Novo Nordisk$49
  • Acella Pharmaceuticals, LLC$45
  • Merck$34
  • plus $109 from 6 others

What the payments were for

  • Food & beverage$410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$410 in reported general payments places this provider in the 40th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024
$8,611
Medicare patients
32
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProgesteroneProgesterone, Micronized13$412

Paid to pharmacies, not to this prescriber.

Other family in Stonewall

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →